New Zealand markets close in 2 hours 24 minutes

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
130.85-1.21 (-0.92%)
At close: 04:00PM EDT
130.36 -0.49 (-0.37%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close132.06
Bid130.36 x 1200
Ask130.90 x 1000
Day's range126.29 - 133.00
52-week range119.01 - 497.49
Avg. volume6,887,137
Market cap52.047B
Beta (5Y monthly)1.70
PE ratio (TTM)3.85
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)

    - Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Senti Bioscien

  • GlobeNewswire

    Leaders: Moderna, Tilray, PharmaDrug, and Vinco; Visionary CEO Highlight New Trends in Vaccines, Biotech, Digital Media, and Consumer Brands

    NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Moderna, Inc. (NASDAQ: MRNA), PharmaDrug (OTC: LMLLF) (CSE: PHRX) Tilray, Inc. (NASDAQ:TLRY) and Vinco Ventures (NASDAQ: BBIG). Today’s emerging technologies and lifestyle megatrends are unleashing trillion dollar market opportunities for disruptive innovation in how we live, work and play. Wall Street Reporter

  • GlobeNewswire

    Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

    WARMINSTER, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. (Nasdaq: MRNA) and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,